Moody's Investors Service adjusted Insulet Corporation's outlook to negative from stable on Friday, while reaffirming several of the company's credit ratings. The agency kept Insulet's Ba2 corporate family rating and Ba2-PD probability of default rating at their existing levels. Moody's also maintained the Ba1 ratings on the company's senior secured term loan and revolving credit facility and the B1 rating on its senior unsecured notes.
The change in outlook reflects elevated credit risk after Insulet announced a second product recall in May 2026 following an earlier recall in March 2026. Moody's noted the combined estimated cost of the recalls is about $80 million, a sum the agency described as manageable from a financial standpoint. Even so, the successive recalls have triggered concerns about product quality and have increased operating risk for a company that depends on a single product family.
Insulet's Ba2 rating rests in part on its strong market position in insulin delivery through the Omnipod wearable system. The company's Omnipod 5 product integrates with continuous glucose monitor systems, offers automated insulin delivery features and includes cloud connectivity. These competitive attributes, Moody's said, support Insulet's credit profile despite the recent operational setbacks.
At the same time, the rating is constrained by Insulet's single product-line dependence, which leaves the business exposed to competition and execution risks including those highlighted by the pair of recalls. Moody's underscored that Insulet's long-term rating trajectory will depend on factors such as diabetes market dynamics, rival products and technologies, patient adoption and volumes, and the company's ability to remediate and manage recall-related issues.
Moody's expects Insulet to retain very good liquidity. The agency cited $480 million in cash and short-term investments on the company's balance sheet as of March 31, 2026, together with strong free cash flow generation. Insulet also has an undrawn $500 million revolving credit facility that matures in 2030; the facility contains a springing leverage covenant set at 6.5x if utilization exceeds 35%.
Context on leverage and financial metrics
Moody's noted Insulet reported debt to EBITDA of around 1.5x as of March 31, 2026. That leverage level, combined with available liquidity, contributed to the agency's decision to maintain the existing ratings even as the outlook was shifted to negative in response to the elevated operating risk brought on by repeated recalls.
What Moody's flagged
- Two product recalls within a short period increased scrutiny of product quality and operations.
- Estimated recall costs are roughly $80 million in total, which Moody's described as financially manageable.
- Insulet's concentrated product portfolio - centered on the Omnipod system - leaves the company vulnerable to competitive and execution pressures.
Taken together, Moody's action signals that while Insulet's credit measures and liquidity remain adequate for now, the agency is closely watching how the company addresses the root causes of the recalls and whether additional quality or operational problems emerge that could weaken its financial profile.